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The three CK isoenzymes. The introduction and ap-
plication of creatine kinase (CK) isoenzymes significantly
improved the sensitivity and specificity of detection of myo-
cardial infarction (I). Elevated plasma creatine kinase, MB
fraction (MB CK) is now regarded as the most sensitive,
specific and cost-effective means of diagnosing acute myo-
cardial infarction (2,3). The recent purification, character-
ization and detection of plasma CK isoenzyme subforms
offers promise for further improvement and new applica-
tions. Creatine kinase is composed of two subunits, each
with a molecular weight of about 41,000. The subunit M,
so designated because of its abundance in muscle, forms
MM CK, the predominant isoenzyme in cardiac and skeletal
muscle. The B subunit, most abundant in the brain, forms
BB CK, which in minimal amounts is also present in organs
such as the gastrointestinal tract. The hybrid form MB CK
is, except for trace amounts, found primarily in the heart,
where it comprises about 15% of total myocardial CK ac-
tivity, the remainder being MM CK. Hence, the specificity
of MB CK is relative for myocardial injury. The two sub-
units M and B combine to form three isoenzyrnes. During
electrophoresis under conventional conditions, MM remains
essentially neutral at the origin, whereas negatively charged
MB and BB exhibit anodal migration. In the 1960s and
1970s occasional reports appeared of additional isoenzymes
but these were usually discarded as artifact. In 1977, Wevers
et al. (4) showed that MM CK, on release into the blood,
exhibited three bands on electrophoresis. They presented
convincing evidence that blood somehow induced the for-
mation of two MM CK molecules with more anodal mi-
gration than the form released from the tissue.
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Technique of chromatofocusing to identify three iso-
enzymes. In an attempt to clarify the mechanism respon-
sible for conversion of tissue MM CK into three isoforms
and to determine their physiologic and diagnostic signifi-
cance, we developed a technique using chromatofocusing
to isolate and purify the plasma isoforms. Results of these
and subsequent studies (5-7) showed a single form of MM
CK to be present in the tissue, whether myocardial or skel-
etal muscle, which, on release into the plasma, is sequen-
tially converted into MM-2, a more negatively charged mol-
ecule, and then into MM-l, whicn is the most negatively
charged. This conversion is due to carboxypeptidase N-in-
duced hydrolysis of the C-terminal lysine of MM CK. On
the basis of hybridization experiments and peptide mapping,
we showed that MM-2 results from removal of lysine, a
positively charged amino acid, from one subunit and MM-l
from removal of lysine from both subunits. Each isoform
of MM CK has a distinct isoelectric point, but the molecular
weight and catalytic activity are the same. The increased
anodal migration of MM-2 and MM-l on electrophoresis
separates them from the parent tissue MM CK. In referring
to the isoforms, a plea is made to conform to the interna-
tional numerical classification of designating the most an-
odal form MM-l followed by MM-2 and the tissue form
MM-3. Amino acid analysis shows lysine to be the C-ter-
minus of MM CK in the electric eel, dog, rabbit and human
(8). Recently, we (9) cloned and sequenced the cDNA for
human MM CK and confirmed lysine to be the C-terminus.
The M subunit of several other species has now been se-
quenced with recombinant DNA techniques, and the C-ter-
minus in each case is lysine (10-12). Carboxypeptidase N
(13), which specifically hydrolyzes C-terminal arginine or
lysine, is a ubiquitous enzyme found in the plasma of all
mammals and vertebrates; thus, it would appear to be uni-
versal that a single tissue form of MM CK, on release into
the plasma, is converted into more negatively charged forms
of MM CK. The C-terminus of the B subunit is also lysine,
but is somehow protected from carboxypeptidase and does
not appear to develop plasma isoforms, However, the M
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subunit of MB CK undergoes hydrolysis; thus, MB CK
exhibits two isoforms after release into the circulation.
Kinetics of three isoforms on myocardial infarction.
Myocardial necrosis is heralded by a marked increase of
plasma MM-3 and MB-2 (tissue forms) over that of the
hydrolyzed forms. Results of studies in patients with acute
myocardial infarction, as well as after cardiac surgery, show
the expected kinetics of the three isoforms for MM CK
(14-16). Unfortunately, there are currently few clinical data
on the MB isoforms. Release of the tissue form MM-3
occurs very early after the onset of infarction and continues
for 24 to 36 hours. The ratio of MM-3 to MM-I reaches a
peak within the first few hours. Shortly after release of
MM-3, there appears an increase in MM-2 and MM-I, and
as the MM-3 decreases. there is a corresponding reciprocal
increase in MM-2 and MM-l. Early reperfusion, which
occurs with cardiac surgery or after successful thrombolytic
therapy, is associated with a more rapid release and dis-
appearance of MM-3. Implicit in the isoform kinetics is the
potential for improved assessment of acute myocardial in-
farction, particularly in reference to the following: I) dating
the onset of myocardial infarction; 2) earlier detection of
infarction; 3) detection of early reperfusion; 4) detection of
coronary reocclusion and early reinfarction; and 5) esti-
mation of infarct size during reperfusion.
Isoenzymes in myocardial infarction before and after
reperfusion. It is highly desirable to diagnose infarction
before thrombolytic therapy and to noninvasively determine
if reperfusion was induced. Elevated plasma MB CK activity
after acute myocardial infarction without reperfusion is first
detected within 4 to 8 hours by conventional electrophoresis,
or within 4 to 6 hours using the more sensitive quantitative
techniques (17). Plasma total and MB CK activities usually
remain within the normal range for the initial 3 to 4 hours
after the onset of symptoms. Baseline plasma CK activity
exhibits a predominance of MM-I isoform of MM CK, that
abruptly changes with release of CK from injured tissue.
The circulation is flooded with MM-3 (tissue form) resulting
in a severalfold increase of the ratio of MM-I to MM-3.
This may occur initially while total plasma CK activity is
within the normal range. The ratio of MM-3 to MM-I reaches
a peak within the first few hours after onset of infarction
and declines gradually as release declines and MM-3 con-
verts to MM-2 and MM-I. Elevated plasma levels of MM-3
in experimental infarction can be detected within I hour of
coronary occlusion. and in humans, within 2 to 3 hours of
the onset of symptoms, whereas total CK is within normal
limits (18). If these results are confirmed and rapid, con-
venient and sensitive assays can be developed, it would also
be possible on admission to determine whether patients with
chest pain should be admitted to a routine or coronary care
unit bed, facilitating treatment that would be more prompt.
appropriate and cost-effective. Currently, only 20 to 35%
of patients admitted to the coronary care unit are subse-
quently confirmed to have acute myocardial infarction. After
successful reperfusion, the plasma MM-3 activity is signif-
icantly elevated within 15 to 30 minutes, permitting a very
rapid diagnosis. Analysis of the MM-3 temporal profile and
extrapolation to the ordinate provide a reliable estimate of
time of onset of infarction.
Identifying successful reperfusion. Clinical noninva-
sive assessment of intravenous thrombolytic therapy is now
being explored intensively. Several clinical markers have
been assessed, including abatement of chest pain and changes
in the ST segment, but none have been found reliable (16).
On successful reperfusion, the plasma CK temporal profile
is one of rapid appearance and disappearance, which is quite
distinct from that exhibited by patients who do not undergo
reperfusion. Initial results using the time to peak MB CK
were encouraging but later were shown to lack specificity.
In a study (19) involving 133 patients with acute myocardial
infarction, the mean rate of decline in the proportion of
MM-3 in patients undergoing successful thrombolysis with
recombinant tissue plasminogen activator (rt-PA) or strep-
tokinase, as documented by coronary angiography, was ap-
proximately twofold greater than in patients with unsuc-
cessfullysis or in patients who did not receive thrombolytic
therapy. The overall diagnostic accuracy for detecting suc-
cessful reperfusion was 82% with a sensitivity of 79% and
a specificity of 75%.
The rate ofdecline in MM-3 proportion as a noninvasive
marker is now being assessed prospectively as an ancillary
study in the Thrombolysis in Myocardial Infarction (TIMI)
trial. A secondary elevation in plasma MB CK has been
shown to be a very sensitive and specific diagnostic marker
for early extension of infarction (early reinfarction). but this
refers to extension occurring 48 hours or more after the
onset of the preceding infarction. Detection of extension
within 24 hours of acute infarction. such as may occur with
reocclusion after thrombolytic therapy, is not reliable with
MB CK. Plasma MB CK activity peaks on an average of
23 hours (range 13 to 28); thus, detection and interpretation
of a secondary elevation against a high background is likely
to be relatively insensitive as well as nonspecific for sec-
ondary elevation during this interval. Because MM-3 de-
clines rapidly, particularly with early reperfusion, secondary
elevation should be reliably detected even after 12 to 18
hours from onset. The potential of MM-3 to detect early
reinfarction and reocclusion is yet to be explored.
Estimation of infarct size. The need for accurate esti-
mation of infarct size in patients with myocardial infarction
during early reperfusion is great (20). The use of infarct
size as an end point considerably reduces the number of
patients required to document efficacy compared with use
of the conventional end point-mortality. For example, to
detect a 20% reduction in mortality with a power function
of 0.8 and a probability value of less than 0.05 in a pop-
ulation having a 15% mortality rate, about 2,000 patients
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are required; in contrast, a similar reduction in infarct size
could be detected with a sample size of only about 350
patients in each group. Infarct size estimated with CK is a
valid end point for clinical trials and has been shown to
correlate closely with clinical variables, including mortality,
and most recently with histologic estimates determined at
postmortem (21). However, estimates of infarct size in the
presence of reperfusion requires a new release ratio. This
release ratio has been determined (22), but estimates using
the new constant have yet to be validated. Quantitative
estimates of the release of MM-3 should provide more ac-
curate estimates and should accelerate progress in this area.
In addition, serial analysis ofMM-3 will provide an accurate
means of knowing when tissue release of CK has ceased
and make it possible for the first time to obtain accurate
estimates of the individual CK disappearance rate and avoid
the present necessity of having to use a mean value. This
would provide more precise estimates of infarct size and be
applicable in patients with or without reperfusion.
Clinical limitations and implications. The quantitative
chromatofocusing technique (7), used initially for detection
and purification of plasma isoforms, though very sensitive
as subsequently shown by others (18), is too cumbersome
for routine clinical or isoelectric focusing (4). The immu-
noblot technique (18) appears sensitive and quantitative but
is extremely tedious and requires several hours to perform.
The use of electrophoresis on high resolution agarose is
simple, convenient, rapid and has the distinctive feature of
being available in all clinical laboratories (23). However,
it is only semiquantitative and, although adequate for most
clinical uses, requires improved sensitivity for early diag-
nosis of myocardial infarction. The potential diagnostic and
therapeutic value of the CK isoenzyme isoforms is quite
significant; however, full exploitation of their potential, par-
ticularly for early diagnosis, is limited at present by the lack
of a simple, rapid quantitative assay. This problem is, how-
ever, surmountable, and it is reasonable to expect a satis-
factory resolution within the very near future.
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